Investing.com – Erytech Pharma ADR reported on Monday third quarter that missed analysts’ forecasts and revenue that topped expectations.
Erytech Pharma ADR announced earnings per share of $-0.353 on revenue of $25.77M. Analysts polled by Investing.com anticipated EPS of $-0.350 on revenue of $2.83M.
Erytech Pharma ADR shares are down 72.34% from the beginning of the year and are trading at $0.650 , down-from-52-week-high.
Erytech Pharma ADR follows other major Healthcare sector earnings this month
Erytech Pharma ADR’s report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on Friday, October 28, 2022 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Read More: Erytech Pharma ADR earnings miss, Revenue beats in Q3